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Introduction
It has been known for some time that peptides derived from polymorphic MHC class II regions are capable of binding to both syngeneic and allogeneic MHC class II molecules (1) (2) (3) . T cell responses to donor-derived MHC class II peptides can be detected during allograft rejection (4) and these responses are capable of inducing donor-specific cytotoxic T lymphocytes in vivo (5) . In a murine syngeneic setting it has been shown for I-A k that T cell responses to two self l-A-derived peptides could be induced following peptide immunization (1) . These peptides, /4 a k 1-18 and /\p k 1-16, could inhibit the proliferation of an antigen-specific l-A k -restricted T cell hybridoma, demonstrating the ability of these peptides to bind self I-A k molecules. These experiments, and others, have demonstrated the importance of indirect recognition of allogeneic class II molecules in the T cell response to an allograft.
An interesting feature of MHC-derived peptides is their ability to exert an immunoregulatory role. In particular, it has been shown that a human MHC class I peptide can induce allograft tolerance in a rat cardiac allograft model (6) . MHC class llderived peptides have also been used to induce oral tolerance in the rat (7) . The use of such peptides in transplantation models has demonstrated that the tolerance induction is specific and long-lived (8) .
Another situation for which such peptides might'be useful is in autoimmunity where, in many cases, target organs are destroyed by autoreactive T cells. Several therapeutic approaches have been successfully tried including anti-CD4 antibodies, anti-MHC class II antibodies and analogs of peptides known to induce disease (9) (10) (11) (12) . These approaches all have potential disadvantages in either inducing widespread immune suppression or in requiring the identification of the disease-causing peptide. Immunoregulatory peptides derived from MHC class I or class II, such as those described by Clayberger et al. (13) , seem to have the property to induce anergy only in those T cells that are activated at the time of administration. Thus, it is possible that peptides derived from MHC class II or class I could have a therapeutic role in autoimmune disease.
We have been studying the non-obese diabetic (NOD) murine model of human type I diabetes (14) . This is characterized by an early infiltration of CD4 + T cells at 3-4 weeks of age, followed by the development of overt diabetes at -30 weeks of age. NOD mice have a unique MHC class II molecule, I-A 9? , which is thought to play an important role in susceptibility to disease. In this report, studies were initiated to determine whether self class II peptides, derived from I-A 97 , would behave the same way in an autoimmune mouse versus a healthy mouse. We performed peptide binding and T cell inhibition experiments to determine whether three peptides derived from I-A9 7 could specifically bind to syngeneic MHC class II molecules. These peptides were also assessed for their ability to bind allogeneic class II molecules, and alanine analogs of one of the peptides were prepared and analyzed in order to determine the important contact residues. Of potential interest is that one peptide derived from l-/4 a s 7 , /4 a 97 63-82YC, appeared to function in an immunoregulatory role, as it was found to behave as a partial agonist.
Methods

Peptides
Synthetic peptides representing residues 437-460 of the heat shock protein 60 (hsp60) (VLGGGCALLRCIPALDSLTPANED), residues 1-16 of the \-A^7 (GDSERHFVHQFKGECY), residues 63-82YC of the \-A a 9 7 (GLQNIAAEKHNLGILTKRSVYC), residues 52-77 of the \-A^7 (ELGRHSAEYYNKQYLERTRA-ELDTAC) and Tap (HPGTVTALVGPNGSGKSTC), and six single alanine-substituted analogs of Mp0 7 1-16 peptide at positions 2, 4, 6, 9, 12 and 14 were prepared using standard methods (15) by the Peptide Facility of the University of Pittsburgh Cancer Institute. All peptides were HPLC purified following synthesis.
The N-terminus of the hsp60 peptide was biotinylated as previously described (16) . Briefly, 5 mg of immuno-pure Nhydroxy succinimidyl biotin (NHS-LC-Biotin; Pierce, Rockford, IL) was added to a 5 mg/ml suspension of peptide in dimethyl formamide (DMF) diluted 1:1 in PBS, pH 7.4, and incubated with stirring at room temperature for 2 h. Biotinylated peptide was purified by HPLC, dried under vacuum and resuspended at 1 mg/ml in PBS.
Mice
Female NOD/MrkTacfBR (NOD) mice were obtained from Taconic (Germantown, NY) and were used at 6-10 weeks of age. The following strains were obtained from the Jackson Laboratory (Bar Harbor, ME): 129/J (H-2 b ), SWR (1-1-29), SJL (H-2 S ) and A.CA/Sn (H-2 f ), and were used at 8-10 weeks of age.
Peptide binding assay
T cell-depleted NOD spleen cells at 2X10 5 cells per 50 (il of DMEM (Gibco, Grand Island, NY), supplemented with 10% FBS, 2 mM L-glutamine, 50 lU/ml penicillin, 50 ng/ml streptomycin, 5X10" 5 M 2-mercaptoethanol and 10 mM HEPES, were incubated for 1.5 h at 37°C with increasing concentrations (0.78-25 nM) of biotinylated hsp60 peptide. Following incubation, the cells were washed in PBS containing 2% FBS, 0.02% NaN 3 (FACS medium) and stained with FITC-avidin (Sigma, St Louis, MO) for 30 min at 4°C. After staining, cells were washed twice, with the last wash in FACS medium containing 1 (xg/ml propidium iodide (PI; Sigma) and resuspended in 200 (il of FACS medium. Cells were analyzed for FITC and PI on a FACStar flow cytometer. Cells were excited at 488 nm with a 3 W argon laser and emission spectra were collected with 530/30 and 585/42 nm band pass filters respectively. A live gate was used in all FACS analyses.
To determine the specificity of binding, T cell-depleted NOD spleen cells were preincubated for 3 h at 37°C with 100-fold molar excess of unlabeled hsp60 peptide, Tap or with 10 ng/ml of the mAb 10.2.16 (anti-l-A k ) (9) or MKD6 (anti-I-A d ) (ATCC, Rockville, MD). At this point the biotinylated peptide was added to a final concentration of 12.5 ^M. The cells were incubated for a further 1.5 h at 37°C, washed and incubated for 30 min at 4°C with FITC-avidin as described above. Similarly, competition with class ll-derived competitor peptides (6.25-up to 100-fold molar excess) was accomplished as described above.
Generation of T cell clones
T cell clones specific for a hsp60-derived peptide (437-460) were generated as previously described (17) . Briefly, a NOD mouse was immunized at the base of the tail with 200 |ag of hsp60 peptide in complete Freund's adjuvant (Difco Detroit, Ml) and a T cell line established. Clone C3.5 was generated by limiting dilution of 3 cells/well and further subcloned at 1 cell/well by placing them in 96-well plates in the presence of 5xiO 5 /well irradiated NOD spleen cells, antigenic peptide and 20 U/ml IL-2. The specificity of clones and line were determined by proliferation assays carried out with either antigenic or irrelevant peptides. This clone was characterized as Th1 type and was maintained by re-stimulation every 10-12 days with 1-2x10 6 /ml irradiated (2500 rad) NOD spleen cells and antigenic peptide (10 |xg/ml). 4 /well) were placed in 96 well plates in the presence of 2x10 5 irradiated antigen-presenting cells (APC) and 15 ng/ml hsp60 peptide in the presence or absence of competitor peptides or mAb. The cells were incubated at 37°C for 42 h and were pulsed with 0.5 (iCi/well [ 3 H]thymidine for the last 18 h. The cells were harvested onto glass fiber strips and [ 3 H]thymidine incorporation was counted in a beta scintillation counter.
Inhibition of T cell proliferation by MHC class ll-derived peptide
C3.5 T cells (2xiO
In the APC pretreatment assays, T cell-depleted and irradiated spleen cells were preincubated for 3 h at 37°C, in medium alone or with competitor peptides at the indicated concentrations. Following this 15 ng/ml of hsp60 peptide was added. The cells were incubated further for 1.5 h, washed and placed (2x10 5 /well) in wells with 2X10 4 T cells. The wells were pulsed and harvested as described above.
In the T cell pretreatment assays, C3.5 cells were incubated in medium or with the competitor peptides at the indicated concentrations for 3 h at 37°C. After washing, the cells were incubated with irradiated APC and 15 ng/ml hsp60 peptide. The cells were then incubated and harvested as described above.
In the anergy induction assays C3.5 cells (5X10 5 cells/ml)
were incubated with irradiated APC (4X10 6 cells/ml) in the presence of the indicated peptides in a six-well plate (final volume of 5 ml). The cells were incubated for 48 h, after which dead cells and APC were removed by centrifugation over Ficoll-Hypaque. These cells were rested for an additional 24 h, counted and placed in a standard proliferation assay with fresh APC and antigenic peptide as described above. In some experiments, cells were removed at 48 h for FACS analysis of cell size and IL-2R a chain expression using the rat mAb PC61.5 (18) . Supematants were also collected after 48 h in order to determine the level of IFN-y production by ELISA assay as previously described (19) .
Results
Specificity of binding of the biotinylated hsp60 peptide to I-A& 7
A binding assay in which I-A 9? expressing cells were incubated with biotinylated hsp60 peptide was used to establish MHC class ll-peptide interactions. The binding of the biotinylated hsp60 peptide to T cell-depleted NOD spleen cells was dose-dependent (Fig. 1a) . The specificity of binding can be seen in Fig. 1 (b) as the binding was nearly completely inhibited by a 100-fold molar excess of unlabeled hsp60 peptide or the mAb 10.2.16 which recognizes the I-A9 7 molecule. A non-specific mAb, MKD6 (anti-l-A d ) and the Tap peptide were unable to block the peptide binding.
Competition of binding of the biotinylated hsp60 by class llderived synthetic peptides
This assay was used to determine whether self peptides derived from I-A^7 could inhibit the binding of the biotinylated hsp60 peptide. In these experiments, cells were preincubated with increasing concentrations of the unlabeled hsp60 peptide or l-A-derived peptides and analyzed by FACS. The data demonstrate that hsp60 and /4p0 7 1-16 peptides were able to block the binding of labeled peptide in a dose-dependent fashion (Fig. 2 ). /4 a 97 63-82YC peptide inhibited the biotinylated hsp60 peptide binding at higher concentrations. The amount of peptide required to achieve a 50% decrease of hsp60 peptide binding to I-A9 7 can be seen in Fig. 2 . From these data it would appear that hsp60 peptide has the highest affinity for I-A9 7 , whereas /y? 7 1-16 and ^763-82YC peptides were less able to compete for hsp60 peptide binding. Similar experiments were performed with the A$ 97 52-17 peptide. We observed a 40% inhibition in binding using a 10-fold molar excess of A$ g7 52-77 peptide (data not shown). The results indicate that this peptide can also bind to the I-A g7 molecule. The binding of one of the peptides (/4p s7 1-16) was analyzed using a set of six alanine analog peptides and it was found that positions 2 and 4 were essential for peptide binding as well as for inhibition of T cell proliferation (data not shown).
We have pursued these studies in different strains of mice to determine whether this was a specific or general phenomenon. From Fig. 3 it can be seen that the hsp60 peptide showed the highest level of binding to I-A9 7 (NOD) and I-A q (SWR) spleen cells. This binding is inhibited by unlabeled hsp60 peptide in all cases. The ,4p 
Inhibition of T cell proliferation by MHC class ll-derived peptides
Experiments were performed to determine whether the MHC class ll-derived peptides were able to inhibit antigen-induced proliferation of the C3.5 clone. The results (Fig. 4a) indicated that all three peptides were able to inhibit the proliferation of this clone when the MHC class ll-derived peptides were added simultaneously with the antigenic peptide, whereas an irrelevant peptide (Tap) was unable to do so. Other controls included the inhibition by an anti I-A k mAb (10.2.16) and the lack of inhibition by an anti I-A d mAb (MKD6) (Fig. 4a) . In addition, the preincubation of the irradiated APC (Fig. 4b) with the l-A9 7 -derived peptides resulted in reduced proliferation of the hsp60-specific T cell line suggesting that these peptides inhibit T cell proliferation by MHC blockade.
The next question we asked was whether any of these peptides could interact directly with the C3.5 clone. In these assays T cells were preincubated, in the absence of any APC, with the MHC class ll-derived peptides for 3 h, washed and then placed in a standard proliferation assay. These studies revealed that only the /4 a 9 7 63-82YC peptide was able to inhibit the antigen-induced proliferation of T cells (Fig. 5a) . Repeated experiments with the other two peptides failed to demonstrate any direct interaction with the T cells, further supporting the suggestion that the inhibition observed previously was due to competition at the level of MHC peptide binding. Figure 5(b) demonstrates that the effects of A^^Q8 2YC peptide were most pronounced at low antigen concentrations.
A a 97 63-82YC is a partial agonist
In order to further characterize the effect of the /A a s 7 63-82YC on the T cell clones experiments were carried out to determine whether this peptide could function as a partial agonist of the C3.5 clone. In these assays C3.5 cells were incubated with the hsp60 peptide (15 ng/ml), A* 97 63-82YC (450 ng/ml) and /y 7 1-16 (450 ng/ml) peptides in the presence of APC. As a positive control for anergy induction the cells were also incubated on plates that had been coated with anti-TCR mAb (10 n.g/ml). Cells were analyzed after 48 h for an increase in cell size and up-regulation of IL-2R a chain expression. Cells that had been incubated with hsp60, /\ a 0 7 63-82YC or anti-TCR mAb were found to have increased in size and to have up-regulated expression of the IL-2R a chain (Fig. 6) . This was not observed in cells incubated with the /Ap g7 1-16 peptide, which were indistinguishable from cells that had been incubated with medium alone. In addition supernatants collected at 48 h were found to contain significant amounts of IFN-y following incubation with hsp60, /\ a 97 63-82YC peptides or anti-TCR coated plates but not with the /4 p 97 1-16 peptide (Fig. 7) . In view of the fact that the /V 7 63-82YC peptide was unable to stimulate proliferation of the C3.5 clone (data not shown) these data suggested that the /4 a 9 7 63-82YC peptide could act as a partial agonist for the C3.5 clone.
A feature of some partial agonist peptides has been their ability to induce T cell anergy (20, 21) and thus experiments were performed in order to determine whether the A a 97 63-82YC peptide could induce anergy in the C3.5 clone. C3.5 cells were incubated with the /A a 9 7 63-82YC peptide in the presence of APC for 48 h, removed from the APC and then rested for a further 24 h, after which time they were assayed for their ability to respond to fresh APC and hsp60 peptide. Cells treated in this way were found to be profoundly hyporesponsive to the second stimulation (Fig. 8) . Cells incubated on anti-TCR-coated plated were also unable to respond to the second antigenic stimulus, whereas cells incubated with the /4p9 7 1-16 peptide were responsive in the subsequent antigenic stimulation. These data suggest therefore that the /4 a s 7 63-82YC peptide does act as a partial agonist and can induce a state of hyporesponsiveness in a hsp60-specific T cell clone.
Discussion
In this study, we synthesized three l-A9 7 -derived peptides, two from the AQ 37 chain (1-16 and 52-77), and one from the A a 9 7 chain (63-82YC), and we examined the ability of these peptides to compete with a biotinylated peptide derived from hsp60 (437-460) for binding to MHC class II molecules. These studies clearly demonstrated that all three l-A9 7 -derived peptides bind self I-A molecules. This binding is functionally significant as these peptides were able to inhibit the proliferation of an antigen-specific T cell clone. For two of the peptides (Ap 97 1-16 and A$ 7 b2-ll) T cell inhibition appeared to be mediated via MHC blockade as preincubation of APC with these peptides resulted in the inhibition of the T cell proliferation. In contrast, the Aa 37 63-82YC peptide appeared to interact with T cell as pretreatment of the Th1 clone with this peptide resulted in reduced proliferative responses to the antigenic peptide. This effect was most pronounced at lower antigen concentrations. This inhibition was not due to the phenomenon of TCR antagonism, as described by De Magistris et al. (22) , since no effect on the T cell proliferative response was observed when /4 a 0 7 63-82YC peptide was added to APC preincubated with the antigenic peptide (data not shown). Rather this peptide appears to act as a partial agonist as demonstrated by an increase in cell size, upregulation of IL-2R a chain expression and IFN-y secretion. In addition, the -4 a 97 63-82YC peptide was able to induce a state of hyporesponsiveness in the hsp60 (437-460)-specific T cell clone. The peptides /\p» 7 1-16 and /y? 7 63-82YC were also found to bind several different I-A alleles. The mouse strains chosen for these assays were all l-E-negative in order to ensure that the binding observed was only involving I-A. Our data demonstrate that the binding of /\p 97 1-16 is not specific for self MHC as this peptide binds to all five MHC class II molecules tested. The /V 7 63-82YC peptide bound to self MHC class II molecule and was able to bind to three of the peptides. (a) T cells (4xiO 5 /ml) were preincubated with/without the indicated concentrations of class llderived peptides for 3 h at 37°C. After washing, 2xio 4 /well peptidepretreated T cells were placed in a proliferation assay with irradiated APC and hsp60 peptide (15 ng/ml). Cells were incubated, pulsed and harvested as described in Fig. 4. (b) T cells (4xiO 5 /ml were preincubated with 375 ng/ml of class ll-derived /4a 97 63-82YC peptide or in medium for 3 h. After washing T cells were placed in the wells as described above with indicated antigen concentrations. Results are the mean (±SD) of triplicate wells representative of at least three different experiments.
depend on the ability of these peptides to be generated by the natural processing of MHC class II molecules which remains to be resolved.
The binding of /4p^71-16 to I-A9 7 appears to follow the same rules as those that govern the binding of antigenic peptides to MHC. In data not shown in this report, alanine analogs of ,4p 97 1-16 were made and, using these analogs in binding assays and T cell proliferation assays, we were able to identify a role in modulation of immune response (24, 25) . In particular, Chicz et al. (24) have proposed that MHC class II molecules may contain many peptides derived from self molecules, including MHC itself, and that these peptides serve as competitors to ensure that only high-affinity foreign peptides bind.
It has recently been shown that the I-A g7 molecule is intrinsically unstable and that it is a poor peptide binder (26) .
In the assays that we performed we did not detect any difference in the ability of I-A^7 to bind the various peptides that we tested, when compared with four other murine strains tested. This is likely to be due to the less stringent nature of the whole cell assay that we have performed as compared to the immunoprecipitations performed by Carrasco-Marin et al. (26) . The whole cell binding assay was specific as the peptide derived from the Tap protein was unable to bind to I-A 97
. The assay described here may therefore prove a useful way of identifying peptides that are capable of binding to I-A9 7 .
The case of the /V 7 63-82YC peptide is interesting as it appears that this peptide may be able to interact directly with T cells. Whether this peptide is actually interacting with TCR or another cell surface structure remains to be determined. It has been shown, however, that a peptide derived from the I-A$ k chain (amino acids 68-83) was able to bind directly to the TCR as determined using a direct binding assay (27) . It was also shown that this peptide could inhibit T cell proliferation and inhibit the binding of an anti-clonotype antibody to the T cell clone (27) . This peptide was derived from the p chain of the I-A k molecule whereas the one that we have studied is derived from the a chain. Both peptides are derived from the a-helical region of the respective I-A chain. Another common feature between these two peptides is that both peptides were engineered with an additional cysteine at one end which may allow the peptides to dimerize and favor more efficient binding to the TCR.
In these studies we have also been able to demonstrate that the /\ a 97 63-82YC peptide can act as a partial agonist to the hsp60 (437-460)-specific T cell clone and that it can induce hyporesponsiveness to subsequent antigenic stimulation. In these studies it was found that the presence of the cysteine did have an influence on the response as the A a 9 7 63-82 peptide was synthesized and it was found to cause an increase in size and to up-regulate IL-2R a chain expression but it was unable to induce IFN-y secretion (data not shown). These data therefore suggest that the a chain sequence is responsible for binding to the TCR. In addition, it is possible that the presence of the cysteine allows the peptide to dimerize and thus cross-link more effectively.
These data are similar to those that have been described for altered peptide ligands in which antigenic peptides are substituted at individual positions and the resulting mutants are unable to induce proliferation but can stimulate IL-4 secretion and induce anergy (28, 29) . This is the first time that a peptide derived from MHC class II has been shown to act as a partial agonist. Nisco et al. (6) have recently shown that a MHC class l-derived peptide can be used to induced allograft tolerance in a rat heart transplant model. This class l-derived peptide was previously shown to inhibit T cell activation by direct interaction with the T cell (30) . It is possible the /A (X £ f7 63-82YC peptide may have a similar effect and such a peptide may prove useful in the therapy of autoimmune disease, and these experiments are underway.
Peptides derived from MHC class II have been used as competitors and antagonist peptides in T cell proliferation assays. Rosloniec et al. (3) showed that the l-^-derived peptides that competed for binding was also able to inhibit T cell proliferation. It has been reported in the collageninduced arthritis model of human rheumatoid arthritis, which can be induced in susceptible H-2 q strains, a peptide derived from the \-A a q chain can be used to inhibit the proliferation of collagen-specific T cell clones (31) . The peptide used in these studies was derived from the same region as the one that we report in this paper. The fact that such a peptide may induce hyporesponsiveness/anergy has important implications for potential immunotherapy in autoimmunity. Thus in an autoimmune disease in which the precipitating antigen is unknown, it may be possible to design an inhibitory peptide(s) derived from the predisposing MHC class II molecules that could modulate disease initiation and progression.
